Wellcome Trust Case Control Consortium

Home
WTCCC1 WTCCC2 WTCCC3
Information
Overview Management Committee WTCCC2 studies
WTCCC2 studies
Ankylosing Spondylitis Barrett's Oesophagus, Oesophageal Adenocarcinoma Bacteraemia Susceptibility Glaucoma Ischaemic Stroke Multiple Sclerosis Pre-eclampsia Parkinsons Disease Psychosis endophenotypes Statin Response Psoriasis Reading and Mathematics Schizophrenia Ulcerative Colitis Visceral Leishmaniasis
Press & publications
Press Release: 28/09/2005 Press Release: 06/06/2007 Publications and presentations
Data access
Access to data Approved Applications CDAC members Data formats FAQ
Open access
Available software
Participant access
Participant Login
Contact
Feedback and queries

Genome Wide Association Study of Bacteraemia Susceptibility

Adrian Hill

Steven J Chapman, Anthony Scott, Thomas Williams.

Bacteraemia, caused by infection of the bloodstream by bacteria, is a common pathway in the progression to death from severe pneumonia, meningitis and sepsis. It accounts for an estimated 3 million deaths annually in children under the age of 5 years - the leading cause of death in children worldwide. Even in developed countries the mortality rate from bacteraemia remains unacceptably high. A key question is why only a proportion of individuals develop invasive disease when asymptomatic carriage of bacteria is widespread. Host genetic factors play an important role in explaining this inter-individual variation in susceptibility, and candidate gene studies have established a small number of replicated susceptibility loci for bacteraemia. Many more genes are likely to be involved, however, and current understanding of the host genetic factors which influence disease susceptibility and outcome remains extremely limited.

The study aims to identify major genetic susceptibility loci for bacteraemia through a genome-wide association study in children from rural coastal Kenya. Identification of major susceptibility loci may translate into clinical benefit, for example through the discovery of novel therapeutic targets.